Psithera Inc. spun out from Roivant and closed a $47.5 million Series A financing while appointing Eric Shaff as president and CEO. The Watertown, Mass. company repositioned itself to develop small‑molecule therapeutics against immune and inflammatory targets using computational platforms inherited through prior acquisitions. Company statements and reporting in December 2025 detailed the financing and leadership changes, framing Psithera’s capital raise as seed funding to advance discovery programs and validate its Quaisar computational platform in immunology and inflammation.